

Phillip Scheinberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6724930/publications.pdf>

Version: 2024-02-01

127
papers

10,162
citations

57719

44
h-index

34964

98
g-index

129
all docs

129
docs citations

129
times ranked

11425
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Standard Immunosuppression Regimen in Severe Aplastic Anemia. <i>New England Journal of Medicine</i> , 2022, 386, 89-90.	13.9	6
2	Immunosuppressive therapy in severe aplastic anemia. <i>Seminars in Hematology</i> , 2022, 59, 21-29.	1.8	9
3	Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia. <i>British Journal of Haematology</i> , 2021, 193, 410-414.	1.2	5
4	Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries. <i>British Journal of Haematology</i> , 2021, 194, 954-969.	1.2	30
5	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. <i>BMJ, The</i> , 2021, 372, n84.	3.0	309
6	Why do Tregs suddenly disappear in aplastic anemia?. <i>Blood</i> , 2020, 136, 779-780.	0.6	1
7	Novel therapeutic choices in immune aplastic anemia. <i>F1000Research</i> , 2020, 9, 1118.	0.8	11
8	Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. <i>Frontiers in Immunology</i> , 2019, 10, 1157.	2.2	133
9	Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. <i>Blood</i> , 2019, 133, 2575-2585.	0.6	77
10	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	0.8	277
11	Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. <i>Blood Advances</i> , 2019, 3, 980-983.	2.5	5
12	Stem cell stimulation continues to pay off in aplastic anaemia. <i>Lancet Haematology,the</i> , 2019, 6, e543-e544.	2.2	5
13	Developing role of eltrombopag in the treatment of aplastic anemia. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 231-235.	0.5	0
14	Activity of eltrombopag in severe aplastic anemia. <i>Blood Advances</i> , 2018, 2, 3054-3062.	2.5	50
15	Recent Advances and Long-Term Results of Medical Treatment of Acquired Aplastic Anemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 609-618.	0.9	14
16	Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study. <i>Annals of Hematology</i> , 2018, 97, 2039-2046.	0.8	15
17	Activity of eltrombopag in severe aplastic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 450-456.	0.9	23
18	AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 445-445.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 229-229.	0.6	2
20	Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 5554-5554.	0.6	0
21	Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. <i>New England Journal of Medicine</i> , 2017, 376, 1540-1550.	13.9	393
22	A plasma microRNA signature as a biomarker for acquired aplastic anemia. <i>Haematologica</i> , 2017, 102, 69-78.	1.7	32
23	Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia. <i>Annals of Hematology</i> , 2017, 96, 1907-1914.	0.8	10
24	Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling. <i>Blood</i> , 2017, 130, 777-777.	0.6	12
25	Danazol Treatment for Telomere Diseases. <i>New England Journal of Medicine</i> , 2016, 374, 1922-1931.	13.9	300
26	How deep can you go into Tregs?. <i>Blood</i> , 2016, 128, 1158-1159.	0.6	0
27	Hematopoietic stem cell transplantation for cutaneous Tâ€cell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil. <i>Journal of Dermatology</i> , 2016, 43, 638-642.	0.6	16
28	Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. <i>Lancet Haematology</i> , 2016, 3, e22-e29.	2.2	33
29	Myeloid Neoplasm Gene Somatic Mutations in Patients with Severe Aplastic Anemia Treated with Eltrombopag and Standard Immunosuppression. <i>Blood</i> , 2016, 128, 727-727.	0.6	1
30	A Plasma microRNA Signature As a Biomarker for Acquired Aplastic Anemia. <i>Blood</i> , 2016, 128, 728-728.	0.6	1
31	Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia. <i>Haematologica</i> , 2015, 100, e345-e347.	1.7	14
32	Answer to "Confounding effect of cyclosporine dosing when comparing horse and rabbit antithymocyte globulin in patients with severe aplastic anemia". <i>Haematologica</i> , 2015, 100, e213-e213.	1.7	0
33	CMVpp65-Specific T Cells Generated from NaÃve T Cell Populations Recognize Atypical but Not Canonical Epitopes and May Be Protective In Vivo. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S51-S52.	2.0	0
34	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. <i>New England Journal of Medicine</i> , 2015, 373, 35-47.	13.9	508
35	CMV-specific T cells generated from naÃve T cells recognize atypical epitopes and may be protective in vivo. <i>Science Translational Medicine</i> , 2015, 7, 285ra63.	5.8	93
36	Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates. <i>Blood</i> , 2015, 126, LBA-2-LBA-2.	0.6	16

#	ARTICLE	IF	CITATIONS
37	Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia. <i>American Journal of Hematology</i> , 2014, 89, 467-469.	2.0	21
38	Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. <i>Blood</i> , 2014, 123, 1818-1825.	0.6	336
39	Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i> . <i>Science</i> , 2014, 345, 1623-1627.	6.0	745
40	Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag. <i>Clinical Rheumatology</i> , 2014, 33, 1347-1349.	1.0	12
41	Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia. <i>American Journal of Hematology</i> , 2014, 89, 571-574.	2.0	43
42	Extending the Option of CMV-Specific T Cells from the CMV-Seronegative Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S131.	2.0	0
43	Long-Term Outcome of Fludarabine-Based Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Debilitating Paroxysmal Nocturnal Hemoglobinuria. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1435-1439.	2.0	20
44	Outcome of children with severe acquired aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine A. <i>Jornal De Pediatria</i> , 2014, 90, 523-527.	0.9	5
45	Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. <i>Blood</i> , 2014, 124, 2820-2823.	0.6	39
46	Outcome of children with severe acquired aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine A. <i>Jornal De Pediatria (Versão Em Português)</i> , 2014, 90, 523-527.	0.2	0
47	In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. <i>Haematologica</i> , 2014, 99, 1433-1440.	1.7	38
48	AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8614-TPS8614.	0.8	0
49	Thymus transplantation restores the repertoires of forkhead box protein 3 (FoxP3) ⁺ and FoxP3 ^{hi} T cells in complete DiGeorge anomaly. <i>Clinical and Experimental Immunology</i> , 2013, 173, 140-149.	1.1	22
50	Prognostic value of telomere attrition in patients with aplastic anemia. <i>International Journal of Hematology</i> , 2013, 97, 553-557.	0.7	14
51	Mesenchymal stromal cells: filling the void of immunosuppressive therapy in aplastic anemia?. <i>Cytotherapy</i> , 2013, 15, 751-752.	0.3	1
52	Aplastic Anemia: What Have We Learned From Animal Models and From the Clinic. <i>Seminars in Hematology</i> , 2013, 50, 156-164.	1.8	45
53	Thymus Transplantation Restores the Repertoire of Foxp3 ⁺ T Cells in Complete DiGeorge Anomaly. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB196.	1.5	0
54	A Pilot Study Of Rituximab In Patients With Moderate Aplastic Anemia, Diamond-Blackfan Anemia and Pure Red Cell Aplasia. <i>Blood</i> , 2013, 122, 2479-2479.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Alemtuzumab Is Safe and Associated With High Response Rates In Selected Patients With Myelodysplastic Syndrome. <i>Blood</i> , 2013, 122, 593-593.	0.6	2
56	HLA and Aplastic Anemia: associations In Large Brazilian Cohorts. <i>Blood</i> , 2013, 122, 1237-1237.	0.6	0
57	The Interferon Gamma Gene Polymorphism In Acquired Aplastic Anemia and Its Association With HLA. <i>Blood</i> , 2013, 122, 1236-1236.	0.6	0
58	Alemtuzumab Achieved Durable Hematologic Response In Heavily Treated T-Large Granular Lymphocytosis Irrespective To STAT3 Mutation Or V-Beta Clone Size. <i>Blood</i> , 2013, 122, 3705-3705.	0.6	1
59	Chemokine Receptor Ccr1 Drives Neutrophil-Mediated Kidney Immunopathology and Mortality in Invasive Candidiasis. <i>PLoS Pathogens</i> , 2012, 8, e1002865.	2.1	102
60	Clonotype and Repertoire Changes Drive the Functional Improvement of HIV-Specific CD8 T Cell Populations under Conditions of Limited Antigenic Stimulation. <i>Journal of Immunology</i> , 2012, 188, 1156-1167.	0.4	38
61	Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2012, 97, 867-873.	1.7	34
62	Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. <i>Blood</i> , 2012, 119, 345-354.	0.6	98
63	How I treat acquired aplastic anemia. <i>Blood</i> , 2012, 120, 1185-1196.	0.6	351
64	Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1616-1623.	1.9	36
65	Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. <i>Leukemia</i> , 2012, 26, 700-707.	3.3	95
66	Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia. <i>New England Journal of Medicine</i> , 2012, 367, 11-19.	13.9	454
67	Aplastic anemia: therapeutic updates in immunosuppression and transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 292-300.	0.9	64
68	Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. <i>Leukemia Research</i> , 2012, 36, 982-989.	0.4	43
69	Aplastic anemia: therapeutic updates in immunosuppression and transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 292-300.	0.9	41
70	Clinical and Genetic Heterogeneity of Telomere Diseases.. <i>Blood</i> , 2012, 120, 2373-2373.	0.6	1
71	Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia. <i>New England Journal of Medicine</i> , 2011, 365, 430-438.	13.9	415
72	Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 291-299.	2.0	31

#	ARTICLE	IF	CITATIONS
73	Alloreactivity Across HLA Barriers Is Mediated by Both Naïve and Antigen-Experienced T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 800-809.	2.0	24
74	Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T _{regs}) with Minimal Loss of in Vivo Functional Activity. <i>Science Translational Medicine</i> , 2011, 3, 83ra41.	5.8	326
75	Current management of severe acquired aplastic anemia. <i>Einstein (Sao Paulo, Brazil)</i> , 2011, 9, 229-235.	0.3	1
76	T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. <i>Blood</i> , 2011, 117, 2691-2699.	0.6	77
77	Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. <i>Haematologica</i> , 2011, 96, 602-606.	1.7	113
78	Decreased Infection-Related Mortality and Improved Survival in Severe Aplastic Anemia in the Past Two Decades. <i>Clinical Infectious Diseases</i> , 2011, 52, 726-735.	2.9	101
79	Reply to R. Tibes et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 4842-4843.	0.8	0
80	Cyclosporine Taper Does Not Prevent Relapse in Severe Aplastic Anemia. <i>Blood</i> , 2011, 118, 2406-2406.	0.6	3
81	Eltrombopag Can Stimulate Trilineage Hematopoiesis with Transfusion Independence in Patients with Refractory Severe Aplastic Anemia: Results From a Phase II Trial. <i>Blood</i> , 2011, 118, 54-54.	0.6	2
82	Different In Vivo Effects of Horse and Rabbit Antithymocyte Globulin in Patients with Severe Aplastic Anemia. <i>Blood</i> , 2011, 118, 2399-2399.	0.6	0
83	Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine. <i>Haematologica</i> , 2010, 95, 1075-1080.	1.7	95
84	Th17 immune responses contribute to the pathophysiology of aplastic anemia. <i>Blood</i> , 2010, 116, 4175-4184.	0.6	149
85	Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. <i>Blood</i> , 2010, 116, 4546-4559.	0.6	41
86	Association of Telomere Length of Peripheral Blood Leukocytes With Hematopoietic Relapse, Malignant Transformation, and Survival in Severe Aplastic Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1358.	3.8	173
87	Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions. <i>Journal of Clinical Oncology</i> , 2010, 28, 5166-5173.	0.8	119
88	Immunosuppression or immunostimulation for aplastic anemia? A blast from the past. <i>Cytotherapy</i> , 2010, 12, 574-575.	0.3	0
89	Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. <i>Haematologica</i> , 2010, 95, 382-387.	1.7	25
90	Posterior Segment Ophthalmic Complications of Aplastic Anemia. <i>Ophthalmic Surgery, Lasers and Imaging</i> , 2010, 41 Online, .	0.5	2

#	ARTICLE	IF	CITATIONS
91	Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. <i>Haematologica</i> , 2009, 94, 1661-1668.	1.7	84
92	Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. <i>British Journal of Haematology</i> , 2009, 144, 206-216.	1.2	181
93	Probiotic-associated high-titer anti- β in a group A platelet donor as a cause of severe hemolytic transfusion reactions. <i>Transfusion</i> , 2009, 49, 1845-1849.	0.8	71
94	Infections in Patients With Aplastic Anemia. <i>Seminars in Hematology</i> , 2009, 46, 269-276.	1.8	73
95	Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. <i>Haematologica</i> , 2009, 94, 348-354.	1.7	147
96	High avidity myeloid leukemia-associated antigen-specific CD8 ⁺ T cells preferentially reside in the bone marrow. <i>Blood</i> , 2009, 113, 2238-2244.	0.6	57
97	The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. <i>Blood</i> , 2009, 114, 5071-5080.	0.6	82
98	Plasma Cytokines Associated with Low Platelet Counts in Aplastic Anemia and Immune Thrombocytopenia. <i>Blood</i> , 2009, 114, 1317-1317.	0.6	0
99	Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8 ⁺ T cells with peptide-major histocompatibility complex class I tetramers. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2008, 73A, 1001-1009.	1.1	49
100	Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. <i>Experimental Hematology</i> , 2008, 36, 1616-1624.	0.2	57
101	Long-Term Outcome of Pediatric Patients with Severe Aplastic Anemia Treated with Antithymocyte Globulin and Cyclosporine. <i>Journal of Pediatrics</i> , 2008, 153, 814-819.e1.	0.9	111
102	Detection of low avidity CD8 ⁺ T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. <i>Journal of Immunological Methods</i> , 2008, 338, 31-39.	0.6	32
103	Regulatory T-cell depletion does not prevent emergence of new CD25 ⁺ FOXP3 ⁺ lymphocytes after antigen stimulation in culture. <i>Cytotherapy</i> , 2008, 10, 152-164.	0.3	8
104	TCR β -Chain Sharing in Human CD8 ⁺ T Cell Responses to Cytomegalovirus and EBV. <i>Journal of Immunology</i> , 2008, 181, 7853-7862.	0.4	124
105	Response: EBV reactivation in the immunosuppressed: to treat or not to treat?. <i>Blood</i> , 2008, 111, 1739-1740.	0.6	6
106	Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. <i>Blood</i> , 2008, 112, 2826-2835.	0.6	562
107	Aplastic anemia. <i>Current Opinion in Hematology</i> , 2008, 15, 162-168.	1.2	223
108	Aplastic anemia. <i>Current Opinion in Internal Medicine</i> , 2008, 7, 338-344.	1.5	1

#	ARTICLE	IF	CITATIONS
109	Circulating Cytokine Profiles of Patients with Acquired Aplastic Anemia and Myelodysplastic Syndrome. <i>Blood</i> , 2008, 112, 1038-1038.	0.6	2
110	Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. <i>Blood</i> , 2007, 109, 3219-3224.	0.6	125
111	Severe Menorrhagia Associated With Thrombocytopenia. <i>Obstetrics and Gynecology</i> , 2007, 110, 913-917.	1.2	8
112	Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional <i>Mycobacterium tuberculosis</i> -specific CD4 ⁺ memory T lymphocyte populations. <i>European Journal of Immunology</i> , 2007, 37, 3089-3100.	1.6	206
113	Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients. <i>Transfusion</i> , 2007, 47, 1250-1253.	0.8	7
114	The clonal composition of human CD4 ⁺ CD25 ⁺ Foxp3 ⁺ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements. <i>Journal of Immunological Methods</i> , 2007, 321, 107-120.	0.6	21
115	Monosomy 7 Detected by FISH at Disease Presentation Is a Marker for Non-Response to Immunosuppression.. <i>Blood</i> , 2007, 110, 1697-1697.	0.6	3
116	High Avidity Leukemia-Associated Antigen-Specific CD8 ⁺ T Cells Preferentially Localize to the Bone Marrow in Patients with Myeloid Malignancies.. <i>Blood</i> , 2007, 110, 2763-2763.	0.6	0
117	Peptide-Major Histocompatibility Complex Class I Tetramers with Enhanced Coreceptor Binding Properties Enable Visualization of Low Avidity Leukemia-Associated Antigen-Specific CD8 ⁺ T Cells.. <i>Blood</i> , 2007, 110, 1343-1343.	0.6	4
118	Current concepts in the pathophysiology and treatment of aplastic anemia. <i>Blood</i> , 2006, 108, 2509-2519.	0.6	766
119	Brief Communication: Successful Treatment of Pure Red-Cell Aplasia with an Anti-Interleukin-2 Receptor Antibody (Daclizumab). <i>Annals of Internal Medicine</i> , 2006, 144, 181.	2.0	13
120	Apparent hemolysis following intravenous antithymocyte globulin treatment in a patient with marrow failure and a paroxysmal nocturnal hemoglobinuria clone. <i>Transfusion</i> , 2006, 46, 1244-1247.	0.8	6
121	Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. <i>British Journal of Haematology</i> , 2006, 133, 606-611.	1.2	143
122	Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. <i>British Journal of Haematology</i> , 2006, 133, 622-627.	1.2	149
123	Alloreactive T cell clonotype recruitment in a mixed lymphocyte reaction: Implications for graft engineering. <i>Experimental Hematology</i> , 2006, 34, 788-795.	0.2	16
124	Treatment of Severe Aplastic Anemia with Combined Immunosuppression: Antithymocyte Globulin (ATG), Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF).. <i>Blood</i> , 2005, 106, 3758-3758.	0.6	0
125	Subclinical EBV and CMV Reactivations Commonly Occur Following Antibody-Based Immunosuppressive Regimens for Patients with Severe Aplastic Anemia.. <i>Blood</i> , 2005, 106, 1428-1428.	0.6	0
126	Stem-cell transplantation for autoimmune diseases. <i>Cytotherapy</i> , 2003, 5, 243-251.	0.3	5

#	ARTICLE	IF	CITATIONS
127	Update in Internal Medicine. Archives of Medical Research, 2000, 31, 329-352.	1.5	0